Natamysiini
Natamysiini is a synthetic antibiotic belonging to the class of macrolide antibiotics. It is used to treat a variety of bacterial infections, including respiratory tract infections, skin and soft tissue infections, and urinary tract infections. Natamysiini works by inhibiting bacterial protein synthesis, specifically targeting the 50S ribosomal subunit.
The drug was first developed in the 1980s and has since been widely used in clinical settings.
Resistance to natamysiini has been observed in certain bacterial strains, particularly in hospitals where the drug
Natamysiini is typically prescribed by healthcare professionals based on the specific bacterial infection and the patient's